Tenofovir Gel in Pregnancy and Lactation

Microbicides are substances, like gels or foams, being developed that can be applied before
intercourse to prevent transmission of HIV. Research has shown that pregnant women are still
at risk of sexual transmission of HIV, and some research has suggested that pregnant women
may be at increased risk of HIV infection. Microbicides may also aid in preventing
mother-to-child transmission of HIV, because they might be a feasible alternative to oral or
intravenous medications in regions where these methods are difficult to implement. In tests
on healthy women the vaginal microbicide tenofovir 1% gel has been safe and well tolerated.
This study will test the safety of tenofovir 1% gel in healthy, pregnant women and healthy,
lactating women.

Participation in this study will last approximately 3 to 10 weeks. Pregnant women will be
followed until approximately 2 weeks after delivery of their children, and lactating women
will be followed for 3 weeks. Pregnant women will be given either the tenofovir 1% gel or a
placebo gel to be applied daily for 7 days. Groups of pregnant women will be further divided
according to how late into pregnancy they enroll.

Pregnant women will have study visits at enrollment, 6 days after enrollment, and at
delivery. They will also participate in phone assessments 1, 3, and 14 days after enrollment
and at delivery.

Lactating women will be given tenofovir 1% gel and have study visits at enrollment and 6
days after enrollment. They will also participate in phone assessments 1, 3, and 14 days
after enrollment.

All participants will complete blood tests, physical exams, and assessments of adverse
events.

Pregnancy cohort, inclusion criteria:

- Willing and able to provide written informed consent to be screened for and take part
in the study, including participation of the infant after delivery

- Willing and able to provide adequate locator information

- Willing and able to communicate in written and spoken English

- HIV uninfected

- Current pregnancy that is viable and a singleton

- Gestational age consistent with the following guidelines:

- For Pregnancy Cohort Group 1, between 37 0/7 and 39 1/7 weeks (inclusive) at the
enrollment visit (Day 0)

- For Pregnancy Cohort Group 2, between 34 0/7 and 36 6/7 weeks (inclusive) at the
enrollment visit (Day 0)

- Pap result consistent with Grade 0 or satisfactory evaluation of a non-Grade 0 Pap
result, per clinical judgment of site investigator or record (IoR)/designee), in the
12 calendar months prior to enrollment

- Willing to abstain from using nonprescribed intravaginal products and practices
(including douching and sex toys) or other investigational agent or device during
study participation

Pregnancy cohort, exclusion criteria:

- History of adverse reaction to any component of tenofovir 1% gel

- Enrollment in any other investigational drug or device trial within 30 days prior to
the enrollment visit (Day 0)

- Currently breastfeeding

- Use of vaginal medications within 48 hours prior to screening or enrollment (Day 0)
(participant may return to complete study procedures after 48 hours have passed since
use of vaginal medication)

- Documented to have any of the following during the current pregnancy:

- Ultrasound evidence of significant fetal congenital anomaly (in the opinion of
the IoR or designee)

- Known rupture of the amniotic membranes

- Known placental/fetal abnormalities that could affect placental transfer (e.g.,
placental abruption, placenta previa, placenta accreta, intrauterine growth
restriction, two-vessel cord, etc.)

- Known maternal disease with predictable negative effect on placental function
(e.g., hypertension, diabetes mellitus, collagen vascular disease)

- Laboratory abnormalities noted at screening, as specified in study protocol

- Diagnosis of sexually transmitted infection (STI), including chlamydia, gonorrhea,
and/or trichomoniasis, in the past 8 weeks prior to enrollment (Day 0), as assessed
by participant report or review of medical record

- Symptomatic vaginitis, including bacterial vaginosis (BV) and vulvovaginal
candidiasis (asymptomatic evidence of BV and/or yeast is not exclusionary) at the
time of enrollment (Day 0)

- Clinically apparent pelvic exam finding of Grade 2 or higher (observed by study
staff) at the enrollment visit

- Use of oral and/or vaginal preparations of antibiotic or antifungal medications at
screening or within 7 days of enrollment (Day 0)

- Any social or medical condition that, in the investigator's opinion, would preclude
informed consent, make study participation unsafe, complicate interpretation of study
outcome data, or otherwise interfere with achieving the study objectives

Lactation cohort, inclusion criteria:

- Willing and able to provide written informed consent to be screened for and take part
in the study

- Willing and able to provide adequate locator information

- Willing and able to communicate in spoken and written English

- HIV uninfected

- At enrollment, currently primarily breastfeeding a single healthy infant between the
ages of 4 and 26 weeks (inclusive)

- Intending to breastfeed during the period of anticipated study participation

- Using an effective method of contraception at enrollment (Day 0) into lactation
cohort and intending to use an effective method for the duration of scheduled study
participation

- Pap result consistent with Grade 0 or satisfactory evaluation of non-Grade 0 Pap
result, per clinical judgment of site IoR/designee, in the 12 calendar months prior
to enrollment (Day 0)

- Willing to abstain from using nonprescribed intravaginal products and practices
(including douching and sex toys) or other investigational agent or device during
study participation

Lactation cohort, mother exclusion criteria:

- Participation in pregnancy cohort

- Infant excluded from participation

- History of adverse reaction to any component of tenofovir 1% gel

- Participation in investigational drug or device trial within 30 days prior to the
enrollment visit (Day 0)

- Use of vaginal medication(s) within 48 hours prior to screening or enrollment (Day 0)
(participant may return to complete study procedures after 48 hours have passed since
use of vaginal medication)

- More than two infant feedings in a single day with nutrition other than own breast
milk (e.g., formula, solids) within 7 days prior to screening or enrollment (Day 0)

- At the time of enrollment (Day 0), participant report or clinical evidence of
insufficient milk supply or mastitis, according to the judgment of the IoR/designee

- Any significant uncontrolled active or chronic cardiovascular, renal, liver,
hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, or
immunologic disorder or infectious disease, as determined by the IoR/designee

- Certain laboratory results, as specified by study protocol

- Diagnosis of STI, including chlamydia, gonorrhea, and/or trichomoniasis, in the 8
weeks prior to enrollment (Day 0), as assessed by participant report or review of
medical record

- Symptomatic vaginitis, including BV and vulvovaginal candidiasis (asymptomatic
evidence of BV and/or yeast is not exclusionary) at the time of enrollment (Day 0)

- Any of the following findings at enrollment:

- Incomplete postpartum involution of the uterus

- Clinically apparent Grade 2 or higher pelvic exam finding (observed by study
staff)

- Use of oral and/or vaginal preparations of antibiotic or antifungal medications at
screening or within 7 days of enrollment (Day 0)

- Any social or medical condition that, in the investigator's opinion, would preclude
informed consent, make study participation unsafe, complicate interpretation of study
outcome data, or otherwise interfere with achieving the study objectives

Lactation cohort, infant inclusion criteria:

- Mother consents for participation of both self and infant in lactation cohort

- In general good health, as determined by clinical judgment of IoR/designee

- Between the ages of 4 and 26 weeks (inclusive) at both screening and enrollment

Lactation cohort, infant exclusion criteria:

- Any social or medical condition that, in the investigator's opinion, would make study
participation unsafe, complicate interpretation of study outcome data, or otherwise
interfere with achieving the study objectives